Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Finished Goods (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Finished Goods for 5 consecutive years, with $14.5 million as the latest value for Q3 2025.

  • Quarterly Finished Goods rose 80.97% to $14.5 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $14.5 million through Sep 2025, up 80.97% year-over-year, with the annual reading at $10.7 million for FY2024, 270.12% up from the prior year.
  • Finished Goods for Q3 2025 was $14.5 million at Rhythm Pharmaceuticals, up from $13.6 million in the prior quarter.
  • The five-year high for Finished Goods was $14.5 million in Q3 2025, with the low at $111000.0 in Q4 2021.
  • Average Finished Goods over 5 years is $5.7 million, with a median of $2.9 million recorded in 2023.
  • The sharpest move saw Finished Goods skyrocketed 75.68% in 2022, then skyrocketed 1384.62% in 2023.
  • Over 5 years, Finished Goods stood at $111000.0 in 2021, then surged by 75.68% to $195000.0 in 2022, then surged by 1384.62% to $2.9 million in 2023, then skyrocketed by 270.12% to $10.7 million in 2024, then soared by 35.71% to $14.5 million in 2025.
  • According to Business Quant data, Finished Goods over the past three periods came in at $14.5 million, $13.6 million, and $12.6 million for Q3 2025, Q2 2025, and Q1 2025 respectively.